Phase I, randomized, double-blind, placebo controlled study to determine the safety, tolerability, and pharmacokinetics of a single escalating dose and repeated doses of CN-105 in healthy adult subjects

Eitemau Tebyg

• A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of JDTic
  gan: Buda, Jeffrey J, et al.
  Cyhoeddwyd: (2015)
• A Double-Blind, Placebo-Controlled Trial Demonstrating the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336
  gan: F. Ivy Carroll, et al.
  Cyhoeddwyd: (2018-07-01)
• A Double-Blind, Placebo-Controlled Trial Demonstrating the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336
  gan: Carroll, F. Ivy, et al.
  Cyhoeddwyd: (2018)
• A Randomized, Placebo-Controlled, Double-Blind, Dose Escalation, Single Dose and Steady State Pharmacokinetics Study of 9cUAB30 in Healthy Volunteers
  gan: Kolesar, Jill M., et al.
  Cyhoeddwyd: (2019)
• Apolipoprotein E mimetic peptide, CN‐105, improves outcomes in ischemic stroke
  gan: Tu, Tian Ming, et al.
  Cyhoeddwyd: (2017)